CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

M F Krummel, J P Allison, M F Krummel, J P Allison

Abstract

The importance of the B7/CD28/CTLA-4 molecules has been established in studies of antigen-presenting cell-derived B7 and its interaction with the T cell costimulatory molecule CD28. CTLA-4, a T cell surface glycoprotein that is related to CD28, can also interact with B7-1 and B7-2. However, less is known about the function of CTLA-4, which is expressed at highest levels after activation. We have generated an antibody to CTLA-4 to investigate the consequences of engagement of this molecule in a carefully defined system using highly purified T cells. We show here that the presence of low levels of B7-2 on freshly explanted T cells can partially inhibit T cell proliferation, and this inhibition is mediated by interactions with CTLA-4. Cross-linking of CTLA-4 together with the TCR and CD28 strongly inhibits proliferation and IL-2 secretion by T cells. Finally, results show that CD28 and CTLA-4 deliver opposing signals that appear to be integrated by the T cell in determining the response to activation. These data strongly suggest that the outcome of T cell antigen receptor stimulation is regulated by CD28 costimulatory signals, as well as inhibitory signals derived from CTLA-4.

References

    1. Immunology. 1993 Sep;80(1):56-61
    1. Science. 1993 Nov 5;262(5135):907-9
    1. J Exp Med. 1994 Mar 1;179(3):1071-6
    1. J Immunol. 1994 Feb 15;152(4):1618-28
    1. Mol Cell Biol. 1994 Apr;14(4):2777-85
    1. J Immunol. 1994 Mar 15;152(6):2686-97
    1. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2834-8
    1. Mol Cell Biol. 1994 May;14(5):3392-402
    1. Nature. 1994 May 26;369(6478):327-9
    1. Cell. 1994 Jun 3;77(5):727-36
    1. Int Immunol. 1994 May;6(5):769-74
    1. Immunol Today. 1994 Jul;15(7):321-31
    1. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9347-51
    1. J Exp Med. 1994 Nov 1;180(5):1841-7
    1. J Exp Med. 1994 Nov 1;180(5):1849-60
    1. J Exp Med. 1995 Jan 1;181(1):351-5
    1. Immunity. 1994 Aug;1(5):405-13
    1. Immunity. 1994 Sep;1(6):443-6
    1. Immunity. 1994 Sep;1(6):501-8
    1. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11054-8
    1. J Immunol. 1981 Jan;126(1):317-21
    1. Immunogenetics. 1981;14(1-2):53-61
    1. Nature. 1987 Jul 16-22;328(6127):267-70
    1. J Immunol Methods. 1989 Jan 17;116(2):251-7
    1. Science. 1989 Apr 21;244(4902):339-43
    1. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4185-9
    1. Proc Natl Acad Sci U S A. 1990 Jul;87(13):5031-5
    1. J Exp Med. 1991 Mar 1;173(3):721-30
    1. J Immunol. 1991 Aug 1;147(3):1037-44
    1. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6575-9
    1. J Exp Med. 1991 Sep 1;174(3):561-9
    1. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):271-5
    1. Nature. 1992 Apr 16;356(6370):607-9
    1. Proc Natl Acad Sci U S A. 1992 May 1;89(9):4210-4
    1. J Immunol. 1992 Jul 1;149(1):24-9
    1. J Immunol. 1992 Jul 15;149(2):380-8
    1. Science. 1992 Aug 7;257(5071):789-92
    1. Science. 1992 Aug 7;257(5071):792-5
    1. J Immunol. 1992 Oct 1;149(7):2402-5
    1. J Exp Med. 1992 Dec 1;176(6):1595-604
    1. Cell. 1993 Mar 12;72(5):767-78
    1. Annu Rev Immunol. 1993;11:191-212
    1. J Immunol. 1993 Oct 1;151(7):3489-99
    1. Eur J Immunol. 1993 Oct;23(10):2572-7
    1. Nature. 1993 Nov 4;366(6450):76-9

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren